Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2008

01-02-2008 | Review

Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease

Authors: Rainer Zenz, Robert Eferl, Clemens Scheinecker, Kurt Redlich, Josef Smolen, Helia B Schonthaler, Lukas Kenner, Erwin Tschachler, Erwin F Wagner

Published in: Arthritis Research & Therapy | Issue 1/2008

Login to get access

Abstract

Activator protein 1 (AP-1) (Fos/Jun) is a transcriptional regulator composed of members of the Fos and Jun families of DNA binding proteins. The functions of AP-1 were initially studied in mouse development as well as in the whole organism through conventional transgenic approaches, but also by gene targeting using knockout strategies. The importance of AP-1 proteins in disease pathways including the inflammatory response became fully apparent through conditional mutagenesis in mice, in particular when employing gene inactivation in a tissue-specific and inducible fashion. Besides the well-documented roles of Fos and Jun proteins in oncogenesis, where these genes can function both as tumor promoters or tumor suppressors, AP-1 proteins are being recognized as regulators of bone and immune cells, a research area termed osteoimmunology. In the present article, we review recent data regarding the functions of AP-1 as a regulator of cytokine expression and an important modulator in inflammatory diseases such as rheumatoid arthritis, psoriasis and psoriatic arthritis. These new data provide a better molecular understanding of disease pathways and should pave the road for the discovery of new targets for therapeutic applications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zenz R, Wagner EF: Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol. 2006, 38: 1043-1049. 10.1016/j.biocel.2005.11.011.CrossRefPubMed Zenz R, Wagner EF: Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol. 2006, 38: 1043-1049. 10.1016/j.biocel.2005.11.011.CrossRefPubMed
2.
go back to reference Wagner EF, Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005, 208: 126-140. 10.1111/j.0105-2896.2005.00332.x.CrossRefPubMed Wagner EF, Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005, 208: 126-140. 10.1111/j.0105-2896.2005.00332.x.CrossRefPubMed
3.
go back to reference Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002, 4: E131-E136. 10.1038/ncb0502-e131.CrossRefPubMed Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002, 4: E131-E136. 10.1038/ncb0502-e131.CrossRefPubMed
4.
go back to reference Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000.CrossRefPubMed Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000.CrossRefPubMed
5.
go back to reference Riera-Sans L, Behrens A: Regulation of alphabeta/gammadelta T cell development by the activator protein 1 transcription factor c-Jun. J Immunol. 2007, 178: 5690-5700.CrossRefPubMed Riera-Sans L, Behrens A: Regulation of alphabeta/gammadelta T cell development by the activator protein 1 transcription factor c-Jun. J Immunol. 2007, 178: 5690-5700.CrossRefPubMed
6.
7.
go back to reference Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, Yaniv M: Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development. 2000, 127: 143-153.PubMed Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, Yaniv M: Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development. 2000, 127: 143-153.PubMed
8.
go back to reference Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, Hui L, Wagner EF: c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev. 2006, 20: 2306-2314. 10.1101/gad.390506.PubMedCentralCrossRefPubMed Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M, Hui L, Wagner EF: c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev. 2006, 20: 2306-2314. 10.1101/gad.390506.PubMedCentralCrossRefPubMed
9.
go back to reference Passegue E, Wagner EF: JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 2000, 19: 2969-2979. 10.1093/emboj/19.12.2969.PubMedCentralCrossRefPubMed Passegue E, Wagner EF: JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. EMBO J. 2000, 19: 2969-2979. 10.1093/emboj/19.12.2969.PubMedCentralCrossRefPubMed
10.
go back to reference Weitzman JB, Fiette L, Matsuo K, Yaniv M: JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000, 6: 1109-1119. 10.1016/S1097-2765(00)00109-X.CrossRefPubMed Weitzman JB, Fiette L, Matsuo K, Yaniv M: JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000, 6: 1109-1119. 10.1016/S1097-2765(00)00109-X.CrossRefPubMed
11.
go back to reference Jochum W, David JP, Elliott C, Wutz A, Plenk H, Matsuo K, Wagner EF: Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med. 2000, 6: 980-984. 10.1038/79676.CrossRefPubMed Jochum W, David JP, Elliott C, Wutz A, Plenk H, Matsuo K, Wagner EF: Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med. 2000, 6: 980-984. 10.1038/79676.CrossRefPubMed
12.
go back to reference Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R: Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med. 2000, 6: 985-990. 10.1038/79683.CrossRefPubMed Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R: Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med. 2000, 6: 985-990. 10.1038/79683.CrossRefPubMed
13.
go back to reference Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF: The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 2004, 23: 2789-2799. 10.1038/sj.emboj.7600282.PubMedCentralCrossRefPubMed Eferl R, Hoebertz A, Schilling AF, Rath M, Karreth F, Kenner L, Amling M, Wagner EF: The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J. 2004, 23: 2789-2799. 10.1038/sj.emboj.7600282.PubMedCentralCrossRefPubMed
14.
go back to reference McHenry JZ, Leon A, Matthaei KI, Cohen DR: Overexpression of fra-2 in transgenic mice perturbs normal eye development. Oncogene. 1998, 17: 1131-1140. 10.1038/sj.onc.1202044.CrossRefPubMed McHenry JZ, Leon A, Matthaei KI, Cohen DR: Overexpression of fra-2 in transgenic mice perturbs normal eye development. Oncogene. 1998, 17: 1131-1140. 10.1038/sj.onc.1202044.CrossRefPubMed
15.
go back to reference Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF: The AP1 transcription factor Fra2 is required for efficient cartilage development. Development. 2004, 131: 5717-5725. 10.1242/dev.01414.CrossRefPubMed Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF: The AP1 transcription factor Fra2 is required for efficient cartilage development. Development. 2004, 131: 5717-5725. 10.1242/dev.01414.CrossRefPubMed
16.
go back to reference Eferl R, Zenz R, Theussl HC, Wagner EF: Simultaneous generation of fra-2 conditional and fra-2 knock-out mice. Genesis. 2007, 45: 447-451. 10.1002/dvg.20311.CrossRefPubMed Eferl R, Zenz R, Theussl HC, Wagner EF: Simultaneous generation of fra-2 conditional and fra-2 knock-out mice. Genesis. 2007, 45: 447-451. 10.1002/dvg.20311.CrossRefPubMed
17.
go back to reference Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, Eferl R, Scheuch H, Szremska A, Amling M, Schorpp-Kistner M, et al: Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol. 2004, 164: 613-623. 10.1083/jcb.200308155.PubMedCentralCrossRefPubMed Kenner L, Hoebertz A, Beil T, Keon N, Karreth F, Eferl R, Scheuch H, Szremska A, Amling M, Schorpp-Kistner M, et al: Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol. 2004, 164: 613-623. 10.1083/jcb.200308155.PubMedCentralCrossRefPubMed
18.
go back to reference Karin M: Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc. 2005, 2: 386-390. 10.1513/pats.200504-034SR. discussion 394–395PubMedCentralCrossRefPubMed Karin M: Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc. 2005, 2: 386-390. 10.1513/pats.200504-034SR. discussion 394–395PubMedCentralCrossRefPubMed
19.
go back to reference Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, et al: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004, 5: 1061-1068. 10.1038/ni1118.CrossRefPubMed Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, et al: Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004, 5: 1061-1068. 10.1038/ni1118.CrossRefPubMed
20.
go back to reference Rincon M, Derijard B, Chow CW, Davis RJ, Flavell RA: Reprogramming the signalling requirement for AP-1 (activator protein-1) activation during differentiation of precursor CD4+T-cells into effector Th1 and Th2 cells. Genes Funct. 1997, 1: 51-68.CrossRefPubMed Rincon M, Derijard B, Chow CW, Davis RJ, Flavell RA: Reprogramming the signalling requirement for AP-1 (activator protein-1) activation during differentiation of precursor CD4+T-cells into effector Th1 and Th2 cells. Genes Funct. 1997, 1: 51-68.CrossRefPubMed
21.
go back to reference Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P: Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J. 2002, 21: 6321-6329. 10.1093/emboj/cdf648.PubMedCentralCrossRefPubMed Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P: Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J. 2002, 21: 6321-6329. 10.1093/emboj/cdf648.PubMedCentralCrossRefPubMed
22.
go back to reference Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, Karin M: Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science. 2004, 306: 271-275. 10.1126/science.1099414.CrossRefPubMed Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, Karin M: Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science. 2004, 306: 271-275. 10.1126/science.1099414.CrossRefPubMed
23.
go back to reference Meixner A, Karreth F, Kenner L, Wagner EF: JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J. 2004, 23: 1325-1335. 10.1038/sj.emboj.7600133.PubMedCentralCrossRefPubMed Meixner A, Karreth F, Kenner L, Wagner EF: JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J. 2004, 23: 1325-1335. 10.1038/sj.emboj.7600133.PubMedCentralCrossRefPubMed
24.
go back to reference Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998, 93: 531-541. 10.1016/S0092-8674(00)81183-6.CrossRefPubMed Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G: DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998, 93: 531-541. 10.1016/S0092-8674(00)81183-6.CrossRefPubMed
25.
go back to reference Smolen JS, Hayer S, Schett G, Redlich K, Aringer M, Kollias G, Wagner E, Steiner G: Autoimmunity and rheumatoid arthritis [abstract]. Autoimmun Rev. 2004, 3 (Suppl 1): S23-PubMed Smolen JS, Hayer S, Schett G, Redlich K, Aringer M, Kollias G, Wagner E, Steiner G: Autoimmunity and rheumatoid arthritis [abstract]. Autoimmun Rev. 2004, 3 (Suppl 1): S23-PubMed
26.
go back to reference Goronzy JJ, Weyand CM: T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004, 16: 212-217. 10.1097/00002281-200405000-00008.CrossRefPubMed Goronzy JJ, Weyand CM: T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004, 16: 212-217. 10.1097/00002281-200405000-00008.CrossRefPubMed
27.
go back to reference Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.CrossRefPubMed Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.CrossRefPubMed
28.
go back to reference Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999, 402: 304-309. 10.1038/46303.CrossRefPubMed Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, et al: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999, 402: 304-309. 10.1038/46303.CrossRefPubMed
29.
go back to reference Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X.CrossRefPubMed
30.
go back to reference O'Gradaigh D, Compston JE: T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. Rheumatology (Oxford). 2004, 43: 122-130. 10.1093/rheumatology/keg447.CrossRef O'Gradaigh D, Compston JE: T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. Rheumatology (Oxford). 2004, 43: 122-130. 10.1093/rheumatology/keg447.CrossRef
31.
go back to reference Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998, 139: 1329-1337. 10.1210/en.139.3.1329.PubMed Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998, 139: 1329-1337. 10.1210/en.139.3.1329.PubMed
32.
go back to reference Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006, 12: 17-25. 10.1016/j.molmed.2005.11.007.CrossRefPubMed Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006, 12: 17-25. 10.1016/j.molmed.2005.11.007.CrossRefPubMed
33.
go back to reference Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004, 279: 26475-26480. 10.1074/jbc.M313973200.CrossRefPubMed Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004, 279: 26475-26480. 10.1074/jbc.M313973200.CrossRefPubMed
34.
go back to reference Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002, 416: 744-749. 10.1038/416744a.CrossRefPubMed Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002, 416: 744-749. 10.1038/416744a.CrossRefPubMed
35.
go back to reference Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11: 529-543. 10.2741/1817.CrossRefPubMed Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci. 2006, 11: 529-543. 10.2741/1817.CrossRefPubMed
36.
go back to reference Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001, 108: 73-81. 10.1172/JCI200112466.PubMedCentralCrossRefPubMed Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001, 108: 73-81. 10.1172/JCI200112466.PubMedCentralCrossRefPubMed
37.
go back to reference Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P: New therapies for treatment of rheumatoid arthritis. Lancet. 2007, 370: 1861-1874. 10.1016/S0140-6736(07)60784-3.CrossRefPubMed Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P: New therapies for treatment of rheumatoid arthritis. Lancet. 2007, 370: 1861-1874. 10.1016/S0140-6736(07)60784-3.CrossRefPubMed
38.
go back to reference Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilia M, Wagner EF: c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell. 2003, 4: 879-889. 10.1016/S1534-5807(03)00161-8.CrossRefPubMed Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilia M, Wagner EF: c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell. 2003, 4: 879-889. 10.1016/S1534-5807(03)00161-8.CrossRefPubMed
39.
go back to reference Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature. 2007, 445: 866-873. 10.1038/nature05663.CrossRefPubMed Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature. 2007, 445: 866-873. 10.1038/nature05663.CrossRefPubMed
40.
go back to reference Mease P: Psoriatic arthritis update. Bull NYU Hosp Jt Dis. 2006, 64: 25-31.PubMed Mease P: Psoriatic arthritis update. Bull NYU Hosp Jt Dis. 2006, 64: 25-31.PubMed
41.
go back to reference Nickoloff BJ: Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med. 2006, 12: 102-106. 10.1016/j.molmed.2006.01.001.CrossRefPubMed Nickoloff BJ: Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med. 2006, 12: 102-106. 10.1016/j.molmed.2006.01.001.CrossRefPubMed
42.
go back to reference Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004, 113: 1664-1675. 10.1172/JCI200422147.PubMedCentralCrossRefPubMed Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004, 113: 1664-1675. 10.1172/JCI200422147.PubMedCentralCrossRefPubMed
43.
go back to reference Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005, 437: 369-375. 10.1038/nature03963.CrossRefPubMed Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005, 437: 369-375. 10.1038/nature03963.CrossRefPubMed
44.
go back to reference Johansen C, Kragballe K, Rasmussen M, Dam TN, Iversen L: Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br J Dermatol. 2004, 151: 600-607. 10.1111/j.1365-2133.2004.06088.x.CrossRefPubMed Johansen C, Kragballe K, Rasmussen M, Dam TN, Iversen L: Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br J Dermatol. 2004, 151: 600-607. 10.1111/j.1365-2133.2004.06088.x.CrossRefPubMed
45.
go back to reference Haider AS, Duculan J, Whynot JA, Krueger JG: Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J Invest Dermatol. 2006, 126: 912-914. 10.1038/sj.jid.5700183.CrossRefPubMed Haider AS, Duculan J, Whynot JA, Krueger JG: Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J Invest Dermatol. 2006, 126: 912-914. 10.1038/sj.jid.5700183.CrossRefPubMed
46.
go back to reference Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N: Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol. 2003, 23: 2564-2576. 10.1128/MCB.23.7.2564-2576.2003.PubMedCentralCrossRefPubMed Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C, Henderson R, Robinson MJ, Hogg N: Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol. 2003, 23: 2564-2576. 10.1128/MCB.23.7.2564-2576.2003.PubMedCentralCrossRefPubMed
47.
go back to reference Conrad C, Nestle FO: Animal models of psoriasis and psoriatic arthritis: an update. Curr Rheumatol Rep. 2006, 8: 342-347. 10.1007/s11926-006-0063-x.CrossRefPubMed Conrad C, Nestle FO: Animal models of psoriasis and psoriatic arthritis: an update. Curr Rheumatol Rep. 2006, 8: 342-347. 10.1007/s11926-006-0063-x.CrossRefPubMed
48.
go back to reference Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT: Mouse models of psoriasis. J Invest Dermatol. 2007, 127: 1292-1308. 10.1038/sj.jid.5700807.CrossRefPubMed Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT: Mouse models of psoriasis. J Invest Dermatol. 2007, 127: 1292-1308. 10.1038/sj.jid.5700807.CrossRefPubMed
49.
go back to reference Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10: 4025-4031.PubMedCentralPubMed Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10: 4025-4031.PubMedCentralPubMed
50.
go back to reference Jo SJ, Park JY, Yoon HS, Youn JI: Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol. 2006, 33: 787-791. 10.1111/j.1346-8138.2006.00180.x.CrossRefPubMed Jo SJ, Park JY, Yoon HS, Youn JI: Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol. 2006, 33: 787-791. 10.1111/j.1346-8138.2006.00180.x.CrossRefPubMed
51.
go back to reference Serarslan G, Guler H, Karazincir S: The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis. Clin Rheumatol. 2007, 26: 1245-1247. 10.1007/s10067-006-0476-y.CrossRefPubMed Serarslan G, Guler H, Karazincir S: The relationship between nail- and distal phalangeal bone involvement severity in patients with psoriasis. Clin Rheumatol. 2007, 26: 1245-1247. 10.1007/s10067-006-0476-y.CrossRefPubMed
Metadata
Title
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease
Authors
Rainer Zenz
Robert Eferl
Clemens Scheinecker
Kurt Redlich
Josef Smolen
Helia B Schonthaler
Lukas Kenner
Erwin Tschachler
Erwin F Wagner
Publication date
01-02-2008
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2008
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2338

Other articles of this Issue 1/2008

Arthritis Research & Therapy 1/2008 Go to the issue